Introduction
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy that is caused by human T-lymphotropic virus type 1 (HTLV-1) infection and commonly affects individuals at an average age of 60 years. It has been reported that the 4-year survival rate was only 10.3%; in particular, patients with an acute or lymphoma subtype showed a dismal prognosis with a 4-year survival rate of approximately 5.0%. 1 Several retrospective studies for ATLL patients younger than 50 years have suggested the possible usefulness of allogeneic hematopoietic SCT (allo-HSCT) with a conventional conditioning chemotherapy regimen. However, the treatment-related mortality by conventional allo-HSCT was high (40-60%), probably due to the disease-specific immune deficiency at diagnosis. [2] [3] [4] This unacceptable level of mortality, even in the case of young patients, critically deters the applicability of conventional allo-HSCT for the general population of ATLL.
To permit the application of allo-HSCT for ATLL in patients aged more than 50 years, we can consider allo-HSCT for ATLL conditioned with reduced-intensity regimen (hereafter, allo-HSCT conditioned with reducedintensity regimen is referred to as 'RIC'). Few retrospective studies have reported the results of RIC for ATLL so far; Shiratori et al. 5 followed up 15 patients after allo-HSCT (including 10 who received RIC) whose median age was 57 years and reported that the OS rate at 3 years reached 73%. Kato et al. 6 investigated the results of 33 patients with allo-HSCT from unrelated donors but this study included only 6 patients receiving RIC. However, our study group had previously activated the first clinical trials of RIC in 2001. These were two trials to clarify the feasibility of RIC: one studied RIC administered with immunosuppressant antithymocyte globulin (ATG) and the other studied RIC without ATG. The results have been already published elsewhere 7, 8 and the treatment-related mortality in both trials collectively decreased to the 20% level, showing that RIC is a promising procedure for ATLL patients more than 50 years of age. In this report, we present the results of long-term follow-up of the two trials and discuss the longitudinal patterns of changes in HTLV-1 proviral load in survivors.
Patients and methods
The patient characteristics have been described in the previous reports. 7, 8 Briefly, patients were eligible if they had ATLL of acute or lymphoma type and were aged between 50 and 70 years. The patients were required to be in either CR or PR at the time of trial registration, and to have a HLA-identical sibling donor. The conditioning regimen consisted of fludarabine (30 mg/m 2 per day) for 5 days and BU (1 mg/kg orally per day) for 2 days. The patients in the first study also received low-dose ATG (2.5 mg/kg per day) for 2 days, whereas those in the second study did not. On day 0, G-CSF-mobilized peripheral blood grafts from their HLA-identical sibling donors were transplanted. To prevent GVHD, we continuously infused CYA (3 mg/kg per day) starting on day À1. The degree of donor-recipient chimerism in peripheral blood mononuclear cells was examined according to the previously reported method. 9 The HTLV-1 proviral load was estimated using blood samples obtained before and at 1, 2, 3, 6, 12 months and every year after transplantation. HTLV-1 proviral DNA was measured by the quantitative PCR amplification of HTLV-1 pX DNA. 10 The detection limit of the HTLV-1 proviral load was 0.5 copies per 1000 cells. The OS curve was estimated by the Kaplan-Meier method.
Results and discussion
Long-term survivors after RIC In all, 15 and 14 patients were registered in the first and second studies, respectively. Eleven (six and five in the first and second studies, respectively) and eight (four in each study) patients died because of ATLL and the treatment, respectively. The last treatment-related death occurred 26 months after RIC. Characteristics of the remaining 10 patients (5 in each study) are summarized in Table 1 . They are currently alive with a median follow-up period of 82 months after RIC (range, 54-100 months). Of the surviving patients, six and four patients had the acute and lymphoma types of ATLL. Of 10 patients, 5 received the grafts from HTLV-1-positive sibling donors. The OS rate at 60 months (5 years) was 34% (95% confidence interval, 18-51). No death was reported beyond 36 months after RIC (Figure 1) .
Of the 10 survivors, 3 developed nonhematological relapse in the skin and/or lymph nodes within a half year after RIC (Table 1) . However, remission was achieved again in these patients after the discontinuation of CYA, immunosuppressive agent, and the administration of additional treatments. In one of these patients, remission was achieved with the cessation of CYA alone. Two other patients were treated with systemic chemotherapy as well as local irradiation or donor lymphocyte infusion after the discontinuation of CYA, and thereafter obtained remission. These three patients survived for 100, 88 and 54 months after RIC, respectively. Because disease recurrence is usually fatal, the clinical course for the three patients was unique. It is suggested that the newly established immunological environment after RIC might have contributed to the eradication of ATLL lesions after early relapse.
All the 10 survivors developed acute GVHD (9 grades I-II and 1 grade III). Chronic GVHD was observed in all but one patient. Although immunosuppressive treatment was discontinued in 9 of the 10 patients, 1 patient is still receiving treatment due to active chronic GVHD. The development of chronic GVHD may suggest the presence of the graft-vs-ATLL effect. Of note is that 8 of 10 survivors received RIC when they were in PR after induction chemotherapy.
Kinetic patterns of HTLV-1 proviral load in long-term survivors Serial changes in the HTLV-1 proviral load after RIC in the 10 long-term survivors are shown in Figure 2 . The changes in the proviral load are heterogeneous but can be roughly classified into three patterns. In the first pattern, the proviral load became undetectable after RIC and continued to remain so; this pattern was seen in three patients. In the second pattern, the proviral load had become undetectable but returned to detectable levels thereafter; this pattern was also seen in three patients, all of whom had received RIC from HTLV-1-negative donors. Finally, in the third pattern, the proviral load had remained at the carrier level in four patients; these patients received the grafts from donors who were HTLV-1 carriers. All the 10 survivors continue to show complete donor chimera during the observation period regardless of the HTLV-1 proviral load level.
We noted that one survivor who was donated graft from an HTLV-1 carrier showed a strikingly high proviral load (nearly 1000 copies) during the first year after RIC; this load then gradually decreased to the carrier level in the second year and the patient is currently surviving without any relapse. A temporary proliferation of HTLV-1-infected (nonleukemic) donor cells, as confirmed by a chimerism analysis, might have occurred due to some unknown etiology.
Conclusion
The long-term follow-up in our prospective studies has shown that one-third of the patients have survived and remain free of ATLL. We have also observed the different patterns of changes in proviral load; the pattern of changes in patients who received the grafts from HTLV-1-positive donors was different from that in patients who received the grafts from HTLV-1-negative donors. In conclusion, this is the first report on the long-term outcomes of ATLL patients who received allo-HSCT, and we have confirmed that RIC from matched sibling donors is a feasible treatment modality for ATLL, and that this treatment has a possible curative effect in patients with ATLL. A load of less than 0.5 copies per 1000 MNC was considered undetectable, which is shown by the shaded area. A solid line indicates a patient who received a transplant from an HTLV-1 carrier donor whereas a dotted line indicates a patient from an HTLV-1-negative donor. Each circle, triangle or square indicates the latest measurement for the patient. Circle shows a pattern that the proviral load became undetectable after RIC and continued to remain so. Triangle shows a pattern that the proviral load had become undetectable but returned to detectable levels thereafter. Square shows a pattern that the proviral load had remained at the carrier level.
